Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Top Cited Papers
Open Access
- 1 August 2017
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 23 (15), 4242-4250
- https://doi.org/10.1158/1078-0432.ccr-16-3133
Abstract
Purpose: Checkpoint inhibitors demonstrate salutary anticancer effects, including long-term remissions. PD-L1 expression/amplification, high mutational burden, and mismatch repair deficiency correlate with response. We have, however, observed a subset of patients who appear to be “hyperprogressors,” with a greatly accelerated rate of tumor growth and clinical deterioration compared with pretherapy, which was also recently reported by Institut Gustave Roussy. The current study investigated potential genomic markers associated with “hyperprogression” after immunotherapy.Experimental Design: Consecutive stage IV cancer patients who received immunotherapies (CTLA-4, PD-1/PD-L1 inhibitors or other [investigational] agents) and had their tumor evaluated by next-generation sequencing were analyzed (N = 155). We defined hyperprogression as time-to-treatment failure (TTF) 50% increase in tumor burden compared with preimmunotherapy imaging, and >2-fold increase in progression pace.Results: Amongst 155 patients, TTF <2 months was seen in all six individuals with MDM2/MDM4 amplification. After anti-PD1/PDL1 monotherapy, four of these patients showed remarkable increases in existing tumor size (55% to 258%), new large masses, and significantly accelerated progression pace (2.3-, 7.1-, 7.2- and 42.3-fold compared with the 2 months before immunotherapy). In multivariate analysis, MDM2/MDM4 and EGFR alterations correlated with TTF <2 months. Two of 10 patients with EGFR alterations were also hyperprogressors (53.6% and 125% increase in tumor size; 35.7- and 41.7-fold increase).Conclusions: Some patients with MDM2 family amplification or EGFR aberrations had poor clinical outcome and significantly increased rate of tumor growth after single-agent checkpoint (PD-1/PD-L1) inhibitors. Genomic profiles may help to identify patients at risk for hyperprogression on immunotherapy. Further investigation is urgently needed. Clin Cancer Res; 23(15); 4242–50. ©2017 AACR.Keywords
Other Versions
Funding Information
- National Cancer Institute (P30 CA016672)
This publication has 28 references indexed in Scilit:
- Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axisJCI Insight, 2013
- MDM2, MDMX and p53 in oncogenesis and cancer therapyNature Reviews Cancer, 2013
- PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible ChemokinesCancer Research, 2012
- Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy ExperienceClinical Cancer Research, 2012
- High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel SequencingCancer Discovery, 2012
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- IFN Regulatory Factor 8 Regulates MDM2 in Germinal Center B CellsPublished by The American Association of Immunologists ,2009
- Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I TrialsJournal of Clinical Oncology, 2009
- Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencingNature Medicine, 2006
- Internal validation of predictive modelsJournal of Clinical Epidemiology, 2001